Literature DB >> 17192452

Prednisone-induced osteoporosis: an overlooked and undertreated adverse effect.

Shinil K Shah1, Gintare T Gecys.   

Abstract

CONTEXT: Glucocorticoids are used for a variety of medical conditions. This class of drugs is arguably the most common cause of iatrogenic osteoporosis, but studies have shown that physicians are not investigating and treating glucocorticoid-induced osteoporosis.
OBJECTIVE: To determine whether primary care physicians (osteopathic and allopathic) are evaluating and treating adult patients at risk for osteoporosis secondary to long-term prednisone use.
METHODS: Electronic medical records from three primary care practices (family medicine, geriatric medicine, and internal medicine) were retrospectively reviewed to identify patients who were taking at least 2.5 mg of prednisone per day for 8 weeks or longer. Records were then grouped according to whether patients had undergone bone mineral density screening and had been given therapy to prevent or treat bone loss. Whether patients had comorbid risk factors for secondary osteoporosis (according to the National Institutes of Health Consensus Development Conference Statement on Osteoporosis) was noted to determine whether treatment was given because of prednisone use or because of the comorbid risk factors. Statistical analysis was performed using a Pearson product moment correlation 2-tailed chi2 test.
RESULTS: The medical records of 49 patients met inclusion criteria (19 men, 30 women; mean age, 61 years; age range, 21-89 years). A statistically significant difference was found in physician evaluation practices for patients with vs patients without comorbid risk factors (82.1% vs 38.1%; P=.002).
CONCLUSION: Primary care physicians do not routinely evaluate patients for osteoporosis secondary to glucocorticoid treatment, especially when patients do not have comorbid risk factors for osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192452

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  9 in total

Review 1.  Skeletal sequelae of cancer and cancer treatment.

Authors:  Charles J Stava; Camilo Jimenez; Mimi I Hu; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2009-05-02       Impact factor: 4.442

2.  Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis.

Authors:  Liao Cui; Ting Li; Yuyu Liu; Le Zhou; Pinghua Li; Bilian Xu; Lianfang Huang; Yan Chen; Yanzhi Liu; Xiaoyan Tian; Webster S S Jee; Tie Wu
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

3.  Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis.

Authors:  Jin Liu; Changwei Lu; Xiaohao Wu; Zongkang Zhang; Jie Li; Baosheng Guo; Defang Li; Chao Liang; Lei Dang; Xiaohua Pan; Songlin Peng; Aiping Lu; Baoting Zhang; Ge Zhang
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

Review 4.  Bioactive Ingredients in Chinese Herbal Medicines That Target Non-coding RNAs: Promising New Choices for Disease Treatment.

Authors:  Yan Dong; Hengwen Chen; Jialiang Gao; Yongmei Liu; Jun Li; Jie Wang
Journal:  Front Pharmacol       Date:  2019-05-21       Impact factor: 5.810

Review 5.  Corticosteroids for COVID-19: worth it or not?

Authors:  Fariya Akter; Yusha Araf; Mohammad Jakir Hosen
Journal:  Mol Biol Rep       Date:  2021-10-13       Impact factor: 2.316

6.  Factors associated with osteoporosis screening and recommendations for osteoporosis screening in older adults.

Authors:  Smita Nayak; Mark S Roberts; Susan L Greenspan
Journal:  J Gen Intern Med       Date:  2009-03-10       Impact factor: 5.128

7.  Factors associated with diagnosis and treatment of osteoporosis in older adults.

Authors:  S Nayak; M S Roberts; S L Greenspan
Journal:  Osteoporos Int       Date:  2009-01-17       Impact factor: 4.507

8.  Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA.

Authors:  C Asche; R Nelson; C McAdam-Marx; M Jhaveri; X Ye
Journal:  Osteoporos Int       Date:  2009-10-02       Impact factor: 4.507

Review 9.  Management issues with exogenous steroid therapy.

Authors:  Hiren Patt; Tushar Bandgar; Anurag Lila; Nalini Shah
Journal:  Indian J Endocrinol Metab       Date:  2013-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.